- Home
- XFOR vs LFCR Comparison
XFOR vs LFCR Comparison
Compare XFOR & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- LFCR
- Stock Information
- Founded
- XFOR 2014
- LFCR 1986
- Country
- XFOR United States
- LFCR United States
- Employees
- XFOR N/A
- LFCR N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- LFCR Biotechnology: Pharmaceutical Preparations
- Sector
- XFOR Health Care
- LFCR Health Care
- Exchange
- XFOR Nasdaq
- LFCR Nasdaq
- Market Cap
- XFOR 320.0M
- LFCR 256.6M
- IPO Year
- XFOR N/A
- LFCR N/A
- Fundamental
- Price
- XFOR $3.52
- LFCR $7.72
- Analyst Decision
- XFOR Strong Buy
- LFCR Buy
- Analyst Count
- XFOR 3
- LFCR 4
- Target Price
- XFOR $34.67
- LFCR $8.00
- AVG Volume (30 Days)
- XFOR 1.7M
- LFCR 155.8K
- Earning Date
- XFOR 11-05-2025
- LFCR 11-06-2025
- Dividend Yield
- XFOR N/A
- LFCR N/A
- EPS Growth
- XFOR N/A
- LFCR N/A
- EPS
- XFOR N/A
- LFCR N/A
- Revenue
- XFOR $33,979,000.00
- LFCR $128,867,000.00
- Revenue This Year
- XFOR $1,307.51
- LFCR $4.72
- Revenue Next Year
- XFOR N/A
- LFCR $10.97
- P/E Ratio
- XFOR N/A
- LFCR N/A
- Revenue Growth
- XFOR 2925.74
- LFCR 0.47
- 52 Week Low
- XFOR $1.35
- LFCR $4.76
- 52 Week High
- XFOR $26.83
- LFCR $8.85
- Technical
- Relative Strength Index (RSI)
- XFOR 49.67
- LFCR 66.09
- Support Level
- XFOR $3.26
- LFCR $6.58
- Resistance Level
- XFOR $3.86
- LFCR $7.24
- Average True Range (ATR)
- XFOR 0.32
- LFCR 0.32
- MACD
- XFOR -0.02
- LFCR 0.09
- Stochastic Oscillator
- XFOR 31.21
- LFCR 96.64
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.